Evidence map›Paper›PMID 37322181›Full record

ReviewNature reviews. Cardiology2023

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia.

Gerald F Watts, Samuel S Gidding, Robert A Hegele, Frederick J Raal, Amy C Sturm, Laney K Jones, Mitchell N Sarkies, Khalid Al-Rasadi, Dirk J Blom, Magdalena Daccord and 12 more

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06045377 (Effect of a Nutraceutical, Containing Red Yeast Rice and Polycosanols), which is not on this map. Cited by 112 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 4 pooled it
63.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06045377 nacompletednot on this map

Effect of a Nutraceutical, Containing Red Yeast Rice and Polycosanols (Armolipid), on Lipid Profile in Children With Moderate and Severe Hypercholesterolemia.

TypeinterventionalSponsorAthens General Children's Hospital "Pan. & Aglaia Kyriakou"Ran2020 to 2022Enrolled90ConditionsDyslipidemias, Children, OnlyArmsEffect of Armolipid on Lipid Profile in Children With Hypercholesterolemia
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 4 syntheses or guidelines pooled it, 201 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 17 institutions in 9 countries.

Gerald F WattsSchool of Medicine, University of Western Australia, Perth, WA, Australia. gerald.watts@uwa.edu.au.ORCID 0000-0003-2276-1524
Samuel S GiddingDepartment of Genomic Health, Geisinger, Danville, PA, USA.
Robert A HegeleDepartment of Medicine and Robarts Research Institute, Schulich School of Medicine, Western University, London, ON, Canada.ORCID 0000-0003-2861-5325
Frederick J RaalDepartment of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-9170-7938
Amy C SturmDepartment of Genomic Health, Geisinger, Danville, PA, USA.
Laney K JonesDepartment of Genomic Health, Geisinger, Danville, PA, USA.ORCID 0000-0002-6182-5634
Mitchell N SarkiesSchool of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Khalid Al-RasadiMedical Research Centre, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
Dirk J BlomDivision of Lipidology and Cape Heart Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0003-3965-5912
Magdalena DaccordFH Europe, Rochester, UK.
Sarah D de FerrantiDepartment of Paediatrics, Harvard Medical School, Boston, MA, USA.
Emanuela FolcoInternational Atherosclerosis Society, Milan, Italy.
Peter LibbyDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1502-502X
Pedro MataFundación Hipercolesterolemia Familiar, Madrid, Spain.
Hapizah M NawawiInstitute of Pathology, Laboratory and Forensic Medicine (I-PPerForM) and Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia.
Uma RamaswamiRoyal Free London NHS Foundation Trust, University College London, London, UK.ORCID 0000-0002-4703-7447
Kausik K RayImperial Centre for Cardiovascular Disease Prevention, Imperial College London, London, UK.
Claudia StefanuttiDepartment of Molecular Medicine, Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Regional Centre for Rare Diseases, Immunohematology and Transfusion Medicine, Umberto I Hospital, 'Sapienza' University of Rome, Rome, Italy.ORCID 0000-0003-3448-2426
Shizuya YamashitaDepartment of Cardiology, Rinku General Medical Center, Osaka, Japan.
Jing PangSchool of Medicine, University of Western Australia, Perth, WA, Australia.ORCID 0000-0002-9700-6948
Gilbert R ThompsonHammersmith Hospital, Imperial College London, London, UK.ORCID 0000-0003-0023-4651
Raul D SantosLipid Clinic, Heart Institute (InCor), University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-9860-6582
Genomic Health (United States) · USThe University of Western Australia · AU23andMe (United States) · USBrigham and Women's Hospital · USEuropean Society of Hypertension · ITHammersmith Hospital · GBHarvard University · USHospital Sungai Buloh · MYImperial College London · GBPoliclinico Umberto I · ITRoyal Free London NHS Foundation Trust · GBSultan Qaboos University · OMThe University of Sydney · AUUniversidade de São Paulo · BRUniversity of Cape Town · ZAUniversity of the Witwatersrand · ZAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This contemporary, international, evidence-informed guidance aims to achieve the greatest good for the greatest number of people with familial hypercholesterolaemia (FH) across different countries. FH, a family of monogenic defects in the hepatic LDL clearance pathway, is a preventable cause of premature coronary artery disease and death. Worldwide, 35 million people have FH, but most remain undiagnosed or undertreated. Current FH care is guided by a useful and diverse group of evidence-based guidelines, with some primarily directed at cholesterol management and some that are country-specific. However, none of these guidelines provides a comprehensive overview of FH care that includes both the lifelong components of clinical practice and strategies for implementation. Therefore, a group of international experts systematically developed this guidance to compile clinical strategies from existing evidence-based guidelines for the detection (screening, diagnosis, genetic testing and counselling) and management (risk stratification, treatment of adults or children with heterozygous or homozygous FH, therapy during pregnancy and use of apheresis) of patients with FH, update evidence-informed clinical recommendations, and develop and integrate consensus-based implementation strategies at the patient, provider and health-care system levels, with the aim of maximizing the potential benefit for at-risk patients and their families worldwide.

Indexed as

AtherosclerosisHyperlipoproteinemia Type IIAdultChildCholesterolFemaleGenetic TestingHumansPregnancyCholesterol

Identifiers

PMID37322181
OpenAlexW4380677035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.